In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, explain how their company guarantees the authenticity of the medications it dispenses, and the measures are in place to prevent counterfeit drugs from entering their supply chain.
Peter Ax: So you know, UpScript really works with pharma companies to bring drugs directly to the consumer, and when we do that, in most cases, we use third party fulfillment sources like an Amazon, like a hub services company or a specialty pharmacy company. But when we do supply the medication ourselves through our own captive pharmacy operation, we pedigree every single pill that comes into our system, every single device, every single medication, it's all pedigree back to the original source of who manufactured it, where it was manufactured, when it was manufactured, and that's an obligation of pharmacies, frankly, so if you're a properly licensed pharmacy, as we have in in our operations, you're assured that that that medication is legitimate, branded properly, etc., and that's true for any properly licensed pharmacy, they should be adhering to that pedigree.
George Jones: We're in the process of preparing for in kind of 95% there the Federal Supply Chain Security Act, so we'll be able to track, track the product, kind of from birth to grave, if you will. We also only buy from either the major wholesalers or directly from the manufacturer of the products as well. So, you know, all those things help us ensure that we are always, always dispensing kind of legitimate, branded or generic products to patients.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Expanding Immune Response Testing to Support Vaccine Development
April 22nd 2025Nigel McCracken, chief operating officer, Virax Biolabs, discusses the expansion of its ViraxImmune platform into areas such as transplant monitoring, vaccine efficacy, latent virus reactivation, and CAR T cell therapy.
New Insights Into T Cell Exhaustion and Inflammation in Long COVID
April 17th 2025Nigel McCracken, chief operating officer, Virax Biolabs, discusses new findings that reveal altered cytokine activity and evidence of T cell exhaustion in long COVID patients, providing deeper insight into post-infection immune disruption.